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Abstract
As the prevalence of cannabis use increases, it is clear that advanced practice registered
nurses (APRN) will be caring for patients who either use cannabis to treat a qualifying
condition or use it recreationally. Current curriculum lacks cannabis-specific knowledge
necessary for APRNs to provide safe and appropriate care to patients using cannabis. The
purpose of this project was to evaluate the impact of a teaching module intended to
provide essential knowledge and clinical implications of medical cannabis for the APRN
student. An educational module was developed based on The National Council of State
Boards of Nursing (NCSBN) National Nursing Guidelines for Medical Marijuana
Education in APRN Nursing Programs. A pre- and post-video survey consisting of nine
knowledge items and one additional perceived importance question was developed and
the project was reviewed by the Rhode Island College IRB as a quality improvement
project. Rhode Island College APRN students were asked to participate by completing
the pre-video survey, watching the educational video, and completing the post-video
survey. A total of 24 students completed the pre-video survey and 19 students completed
the post-video survey. The mean knowledge scores prior to the educational video ranged
from “very poor” to “undecided” and improved to “somewhat good” to “very good”
following the video. All participants perceived the importance of integrating cannabis
education into the APRN curriculum as “moderately” or “extremely” important on both
pre- and post-video surveys. Nursing regulatory organizations, together with accredited
academic institutions, must evaluate current gaps in curriculum and work towards
integrating cannabis-specific content. APRN students must have essential knowledge and
clinical implications of medical cannabis in order to provide safe and appropriate care to
patients using cannabis.
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Development of an Educational Module related to Medical Marijuana for
Advanced Practice Registered Nurse Curriculum
Background/Statement of the Problem
Marijuana, also known as cannabis, has been present in our society throughout
history with varying levels of acceptance and legality (Bridgeman & Abazia, 2017).
Public support for cannabis use over the past 10 years or so has led to a significant
increase in its use. As of March 2020, 33 states, District of Columbia, Guam, Puerto
Rico, and the U.S. Virgin Islands have approved medical marijuana/cannabis programs
for patients with certification of a qualifying condition, while 14 states and territories
have approved marijuana for adult recreational use (National Conference of State
Legislatures (NCSL), 2020).
Due to rapid change in societal attitudes towards cannabis and its increasing use,
nurses and advanced practice registered nurses (APRNs) will undoubtedly be caring for
patients who either use cannabis to treat a qualifying condition or use it recreationally. As
cannabis has been classified as a Schedule I Controlled Substance following the Federal
Comprehensive Drug Abuse Prevention and Control Act of 1970, research on efficacy,
indications, and long-term effects has been limited and lacking. Pre-licensure and APRN
curriculum have subsequently lacked instruction related to the pharmacology, physiologic
effects, uses, neurological symptoms, drug-to-drug interactions, and adverse effects of
cannabis.
In order to better ensure that APRNs provide safe and appropriate patient care,
cannabis-specific curriculum content is necessary. Curriculum must not only provide
knowledge related to the current state of legalization and research, but also the
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endocannabinoid system, pharmacology, and most importantly, safety considerations for
the patient using cannabis. The purpose of this project is to evaluate the impact of a
teaching module intended to provide essential knowledge and clinical implications of
medical cannabis for the APRN student.
Next, the review of the literature will be presented.
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Literature Review
The Cannabis Plant and Historical Use
Cannabis is a generic term used to describe plants belonging to the genus
Cannabis sativa, Cannabis indica, and Cannabis ruderalis. The 1961 United Nations
Single Convention on Narcotic Drugs more specifically defined cannabis as “the
flowering or fruiting tops of the cannabis plant from which resin has not been extracted”
(Madras, 2015, p. 3). With origins dating back more than 5,000 years, cannabis had been
widely used as a patent medication in the United States during the 19th and early 20th
centuries. Cannabis was described in the 3rd edition of the U.S. Pharmacopoeia (U.S.P.)
for the first time in 1850 under the name of Extractum Cannabis or Extract of Hemp.
More than 20 prescription medications containing cannabis were sold at U.S. pharmacies
between 1850 and 1937 and U.S. medical practices used these medications to treat a wide
range of ailments (Bridgeman & Abazia, 2017).
Regulation of cannabis and increased restrictions began around 1906 after which
prohibitions and state-by-state regulations eventually led to the passage of the Marihuana
Tax Act of 1937. Cannabis was dropped from the U.S.P. in 1942 and as a result, legal
penalties for possession of cannabis continued to increase throughout the 1950s. The
passage of the U.S. Drug Enforcement Agency’s (DEA) Comprehensive Drug Abuse
Prevention and Control Act of 1970 officially outlawed cannabis for any use (including
medical) by classifying it as a Schedule I Controlled Substance (Bridgeman & Abazia,
2017).
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As a Schedule I Controlled Substance, the cannabis plant has been defined as
“having high potential for abuse, no currently accepted medicinal use in treatment in the
United States, and a lack of accepted safety data for use of the treatment under medical
supervision” (Bridgeman & Abazia, 2017, p. 180). The plant contains at least 750
chemicals including over 104 different cannabinoids including dronabinol, also known at
9-tetrahydrocannabinol, or THC, cannabidiol (CBD), and cannabinol (CBN).
Tetrahydrocannabinol (THC) is the primary psychoactive compound, while CBD is the
non-psychoactive compound. Despite criminalization and legislative actions limiting use,
research, and distribution, cannabis has continued to be the most cultivated, trafficked,
and abused illicit drug worldwide (Madras, 2015).
Recent efforts to revive cannabis as a medicine have been driven by multiple
factors, with the most prominent being the inability of current medical approaches and
pharmaceuticals to provide symptom relieve to individuals suffering from debilitating
chronic disease. Current cannabis consumption has reached an all-time high, with an
annual prevalence rate of approximately 147 million individuals, or nearly 2.5% of the
global population (Madras, 2015). The 2016 National Survey on Drug Use and Health
results estimated 24.0 million Americans aged 12 years of age or older reported current
cannabis use with 8.9 percent of the population aged 12 years or older reported use within
the previous month. Not only has the percentage of people aged 12 years or older
reporting current cannabis has increased from 2002 to 2015, but the increase in use
among this younger age group is also greater than the increase in use reported by adult
age groups 18 to 25, and 26 or older. (Substance Abuse and Mental Health Services
Administration, 2017)
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Prevalence reports consistently demonstrate that cannabis use for both
recreational and medicinal purposes continues to rise (Madras, 2015), while legislative
actions, ballot measures, and public opinion polls also reflect increased societal
acceptance of cannabis use, especially for medical purposes. For example, the 2016
Gallup poll on American’s views on legalizing cannabis indicated that 60% of the
population surveyed believed cannabis should be legalized. Despite continued
controversies surrounding the legal, ethical, and social implications of cannabis, as of
March 2020, 33 states, District of Columbia, Guam, Puerto Rico, and the U.S. Virgin
Island have approved medical use and 14 states have approved the use of cannabis
recreationally (NCSL, 2020).
Federal and State Legislation through 2019
Classification of cannabis as a Schedule I Controlled Substance both prohibits
practitioners from prescribing cannabis and also prohibits research using cannabis, except
for federally funded research under the oversight of the National Institute on Drug Abuse
(U.S. Food and Drug Administration [FDA], 2019). Despite Drug Enforcement
Administration (DEA) classification and federal law, individual states have instituted
varying legal approaches to authorizing medical marijuana programs over the past few
decades, with more recent efforts focusing on introducing federal bills in an effort to
reschedule cannabis. In 2016, the Food and Drug Administration (FDA) requested a
scientific and medical evaluation and scheduling recommendation from the Department
of Health and Human Services (HHS). The report and recommendations concluded that
marijuana has a high potential for abuse, has no currently accepted medical use in
treatment in the United States, and lacks accepted safety for use under medical
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supervision (Drug Enforcement Administration [DEA], 2016); thus, the DEA denied
petitions to reschedule cannabis as a Schedule II Controlled Substance. The DEA did,
however, recognize the lack of scientific study on cannabis and announced a policy
change which expanded the number of DEA-registered cannabis manufacturers to
increase the supply of cannabis for FDA-authorized research. (The National Council of
State Boards of Nursing [NCSBN], 2018)
In terms of state legislation, each jurisdiction’s medical marijuana program, or
MMP, is unique, with state-specific statues in place which differ in provisions regarding
the process for procuring a certification for the use of cannabis, the amount of cannabis
that can be distributed to an individual, legal protections, designation of caregivers, and
health care provider responsibility. Medical marijuana programs also have differing
qualifying conditions/diagnoses, disease states, or symptoms that enable a patient to
obtain certification and register with the state as a medical marijuana patient. (NCSBN,
2018) There are 57 qualifying conditions included among the different jurisdictional
laws, with the most common being: ALS; Alzheimer’s disease; arthritis; cachexia;
cancer; Chron’s disease and other irritable bowel syndromes; epilepsy or seizure
disorder; glaucoma; hepatitis C; HIV/AIDS; nausea; neuropathies; pain; Parkinson’s
disease; persistent muscle spasms (including multiple sclerosis); post-traumatic stress
disorder; sickle cell disease; and terminal illness (Madras, 2015; NCSBN, 2018).
The National Conference of State Legislatures (NCSL, 2020) provides useful
state-specific medical marijuana resources and guidelines for practitioners to become
knowledgeable of their role. For example, as federal law prohibits practitioners from
prescribing cannabis, some MMPs require an established and ongoing health care
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provider-patient relationship in order to certify, while others require just a consultation
and written recommendation. A few MMPs allow advanced practice registered nurses
(APRNs) to certify, but most only allow medical doctors (MDs), with some MMP
programs requiring practitioners to undergo specific training in order to be a participating
provider. Medical marijuana programs also have provisions for hospice providers,
nursing, medical facilities, personal care attendants, or home health aides to act as a
designated caregiver for the administration of medical marijuana to ill patients (NCSBN,
2018; NCSL, 2020).
Use of Cannabis for Medical Purposes
Currently, the U.S. FDA does not approve the application of the cannabis plant
for the treatment of any disease or condition; however, one cannabis-derived and three
cannabis-related drug products have been approved and are available with a prescription
from a licensed healthcare provider. Epidiolex, which contains a purified form of CBD
has been approved for the treatment of seizures, while Marinol and Syndros, which
include the psychoactive ingredient THC, have been approved for use as an anti-emetic,
appetite stimulant, multiple sclerosis treatment, and for spasticity, respectively. Cesamet,
approved to treat severe nausea and vomiting caused by cancer drug treatment, contains
the active ingredient nabilone, which is a synthetic chemical similar to THC. (Medscape,
2006; FDA, 2019).
Whiting and colleagues (2015) defined medical cannabis as the use of the
unprocessed cannabis plant, not a prescription pharmaceutical, for medical therapy to
treat disease or alleviate symptoms. In order to use cannabis for medical purposes, MMPs
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have established conditions which qualify a patient to use cannabis (NCSBN, 2018).
However, the NCSBN (2018) review revealed that such conditions have generally been
included based on limited availability of clinical research, or because of symptoms they
share with conditions better studied in the literature. For example, the more general
qualifying conditions such as chronic pain, neuropathies, and nausea are the most
researched symptoms associated with medical cannabis. Although research comparing
the effects of cannabis against other standard medications do exist, clinical trials are
small in number, with varying risk of bias. As a result, research has not been able to
definitively specify indications, dosage, route, safety, adverse effects, and long-term
effects of cannabis, let alone clinical guidelines for practitioners (NCSBN, 2018).
The most prominent and thorough reports and review of the medical cannabis
literature have been conducted by the World Health Organization (WHO) (Madras,
2015), Whiting and colleagues (2015), and The National Academy of Sciences (2017).
The WHO report does not provide a comprehensive review of the literature, but rather
summarizes evidence of cannabis for medicinal use globally, citing sources from primary
manuscripts and 10 meta-analyses. It highlights therapeutic indications and
considerations for neurological diseases and symptoms, AIDS wasting, cachexia and
appetite enhancement, cancer and cancer-related symptom management, Crohn’s disease,
Post-traumatic stress disorder (PTSD), and glaucoma (Madras, 2015).
The WHO report used an international survey by Hazekamp, Ware, Muller-Vahl,
Abrams, and Grotenhermen (2013) to demonstrate the global use of medical cannabis.
Respondents (n = 953) from the United States, Germany, Canada, France, the
Netherlands, and Spain were self-reported users of cannabis for medicinal purposes,
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generally male (64%), and the mean age was 40.7. This population reported using
cannabis for back pain (11.9%), sleeping disorders (6.9%), depression (6.7%), injury or
accident-generated pain (6.2%), and multiple sclerosis (4.1%).
Whiting et al. (2015) published the highly regarded medical cannabis resource
following a systematic review to determine the benefits and adverse events (AEs) of
cannabis. A total of 79 randomized clinical trials (6,462 participants) comparing cannabis
with usual care, placebo, or no treatment for the following indications were included:
nausea and vomiting due to chemotherapy; appetite stimulation in HIV/AIDS; chronic
pain; spasticity due to multiple sclerosis or paraplegia; depression; anxiety disorder; sleep
disorder; psychosis; glaucoma; or Tourette’s syndrome. The main outcomes and
measures were patient-relevant and disease-specific outcomes, activities of daily living,
quality of life, global impression of change, and AEs. Common AEs reported included
dizziness, dry mouth, nausea, fatigue, somnolence, euphoria, vomiting, disorientation,
drowsiness, confusion, loss of balance, and hallucination. Study quality was assessed
using the Cochrane risk of bias tool, all review stages were conducted independently by
two reviewers, and data were pooled using random-effects meta-analysis.
Four trials (5%) were judged at low risk of bias, 55 (70%) high risk, and 20 (25%)
unclear risk; however, the major source of bias was determined to be incomplete outcome
data, with more than 50 percent of trials reporting unacceptably high drop-out rates
among cannabis-naïve subjects. Results demonstrated that most trials showed
improvement in symptoms associated with cannabis use; however, the associations did
not reach statistical significance in all trials. Compared with placebo, cannabis was
associated with a greater average number of patients showing a complete nausea and
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vomiting response (47% vs. 20%; odds ratio 3.82 [95% Cl, 1.55-9.42]; 3 trials), reduction
in pain (37% vs. 31%; odds ratio 1.41 [95% Cl, 0.99-2.00]; 8 trials), a greater average
reduction in numerical rating scale pain assessment (on a 1-10-point scale; weighted
mean difference -0.46 [95% Cl, -0.08 to -0.11]; 6 trials), and average reduction in the
Ashworth spasticity scale (weighted mean difference -0.12 [95% Ci, -0.24 to 0.01]; 5
trials). Studies found an increased risk of short-term AEs with cannabis use, including
dizziness, dry mouth, nausea, fatigue, somnolence, euphoria, vomiting, disorientation,
drowsiness, confusion, loss of balance, and hallucination (Whiting et al., 2015). Whiting
et al. concluded that moderate-quality evidence existed supporting the use of cannabis for
the treatment of chronic pain and spasticity while low-quality evidence suggested that
cannabis was associated with improvements in nausea and vomiting due to
chemotherapy, weight gain in HIV infection, sleep disorders, and Tourette syndrome.
In the National Academies of Sciences, Engineering, and Medicine 2017 report,
The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and
Recommendations for Research, experts developed a standard language to categorize the
weight of the evidence for cannabis used medicinally for specific health conditions.
“Conclusive” evidence existed when strong evidence from randomized controlled trials,
and/or many good-quality studies supported the conclusion that cannabis was an effective
or ineffective treatment for the health condition. “Substantial” evidence existed when
several supportive good-quality studies existed with very few or no credible opposing
findings. “Moderate” evidence referred to the existence of “some” evidence but with
identified limitations, such as chance, bias, and confounding factors, that could not be
ruled out with reasonable confidence. “Limited” evidence was determined when there
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were supportive findings from fair-quality studies or mixed findings; a significant amount
of uncertainty existed. Finally, “insufficient” evidence was reported when there were
mixed findings, a single poor study, or no studies at all. (National Academies, 2017)
Conclusive or substantial evidence was determined for therapeutic use of cannabis
for the treatment of chronic pain, as an antiemetic in the treatment of chemotherapyinduced nausea and vomiting, and in the improvement of patient-reported multiple
sclerosis spasticity symptoms. (National Academies, 2017) Moderate evidence supported
cannabis being effective for improving short-term sleep outcomes in individuals with
sleep disturbances associated with obstructive sleep apnea syndrome, fibromyalgia,
chronic pain, and multiple sclerosis (NCSBN, 2018). A greater amount of substantial
evidence suggested adverse outcomes of cannabis such as the statistical association
between cannabis smoking and worse respiratory symptoms, more frequent bronchitis,
increased risk of motor vehicle crashes, lower birth weight of offspring, development of
schizophrenia or other psychoses, and development of problematic cannabis use
(National Academies, 2017).
A review of the literature searching all scholarly articles related to cannabis and
its’ derivatives and the qualifying conditions listed by jurisdiction through February of
2018 was completed by the NCSBN to inform the establishment of the National Nursing
Guidelines for Medical Marijuana published in July 2018. Their review highlighted
evidence that cannabinoids underperformed against standard first-lime medical
treatments for pain, nausea, and cachexia, namely megestrol acetate, ondansetron, and
dihydrocodeine respectively and showed effects comparable to tramadol and pregabalin.
Cannabis was shown to carry its’ own set of AEs, with one risk being that patients may
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forego effective standard medications in favor of cannabis. The review validated the
moderate- to high-quality evidence supporting cannabis as an effective treatment for
cachexia, chemotherapy-induced nausea and vomiting, pain, chronic pain, neuropathies,
spasticity, reduction in seizure frequency, reduction in PTSD nightmares, and
improvement in ticks. Other research by Fox et al. and Greenberg et al., both cited in
NCSBN (2018), posited, however, that improvements in other symptomatology might be
related to the more general effects of cannabis, including sedation, appetite stimulation
and euphoria, which mask symptoms and increase a subjective sense of well-being
leading to improved self-reported quality of life in study participants (NCSBN, 2018).
Physiologic, Therapeutic, and Adverse Effects of Cannabis
The endocannabinoid system. Although the cannabinoid signaling system is
ancient, existing in invertebrates and advanced vertebrate organisms (Madras, 2015), the
discovery of how cannabis interacts with the body has been a slow one. The brain’s
opiate receptor was identified in 1973, but it wasn’t until 1988 that a government-funded
study by Allyn Howlett and William Devane determined not only that the mammalian
brain has receptor sites that respond to compounds found in cannabis, but also that these
receptors are the most abundant type of neurotransmitter receptor in the brain (Moore,
2018).
Over the last 25 years, the endocannabinoid system (ECS) has emerged as an
important neuromodulatory system that plays an important role in central nervous system
(CNS) development, synaptic plasticity, and the response to endogenous and
environmental insults (Lu & Mackie, 2016). The ECS has four main components: G
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protein-coupled cannabinoid CB1 and CB2 receptors; endogenous endocannabinoids, or
lipids, produced by the body which target these receptors (five endocannabinoids have
been identified as compared to over 100 detected in the cannabis plant (Grotenhermen,
2004); enzymes that catalyze or break down endocannabinoids for use by the body; and
mechanisms involved in synaptic and cell messaging (Lu & Mackie, 2016; Madras,
2015).
Function of the endocannabinoid system. Endocannabinoids play a
fundamental role in regulating pleasure, memory, thinking, concentration, body
movement, awareness of time, appetite, pain, sensory processing, and brain development
(Madras, 2015). In the brain and CNS, endocannabinoid signaling controls excitatory and
inhibitory synaptic transmission and regulatory functions in the brain through many
intricate mechanisms. This signaling guides neural stem cell survival and proliferation,
modulates the extent of brain damage resulting from mechanical, blood flow, or other
forms of injury, and coordinates sensory input, which in turn regulates neurogenesis,
appetite, nausea, sleep, neurotransmitters, seizure activity, motor function, and cognitive
function (Kumar, Chambers, & Pertwee, 2001; Madras, 2015).
In peripheral tissues, endocannabinoid signaling accounts for effects throughout
the intestinal mucosa such as inhibition of gastrointestinal motility and gastric emptying.
Increased cardiac output, myocardial oxygen requirement, and tachycardia commonly
result from endocannabinoid activation inhibiting the vagal nerve (Grotenhermen, 2004).
Other peripheral effects of cannabinoids include increased liver cell metabolism;
increased activity of immune cells; increased energy metabolism in muscle cells and the
formation of new muscle fibers; regulation of critical stages of pregnancy and the
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preservation of normal sperm function; and perhaps respiratory urinary system function
(Kumar et al., 2001; Madras, 2015).
Pharmacology. The effects of endocannabinoids are primarily mediated by CB1
and CB2 receptors. CB1 receptors are abundant in the CNS, particularly on axon and preterminal axon segments in the cerebellum, hippocampus, cortex, and basal ganglia.
Activation of these CNS receptors is responsible for the effects of cannabinoids on
cognition, coordination, learning and memory, cognitive function, executive function and
control, integration of sensory input, motor control, and planning (Lu & Mackie, 2016;
Madras, 2015). CB1 receptors have also been found in the central striatum responsible
for prediction and the feeling of reward, the amygdala responsible for feelings of anxiety,
emotion, and fear, the hypothalamus controlling appetite, hormone levels, and sexual
behavior, and the brain stem and spinal cord which control vomiting and pain perception.
CB2 receptors are expressed at much lower levels in the CNS and are primarily present in
microglia which are the macrophages that act as the primary immune system of the brain
and spinal cord. These receptors are also found in vascular tissue, on immune cells, and
within the hematopoietic system which consists of bone marrow, spleen, thymus and
lymph nodes. (Lu & Mackie, 2016; Madras, 2015) In addition to CB1 and CB2 receptors,
several other receptor subtypes have been reported to interact with cannabinoids (Zou &
Kumar, 2018).
The mechanism of action of cannabinoids has been established mainly based on
THC’s agonistic action at the cannabinoid receptors (Grotenhermen, 2004). Increased
interest in cannabidiol (CBD) and its’ unique therapeutic uses has led to ongoing
investigation into its mechanism of action. Unlike THC, CBD does not activate CB1 and
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CB2 receptors, which accounts for its lack of psychotropic activity. Cannabidiol has been
found to potentiate some of THC’s beneficial effects as it reduces THC’s psychoactivity,
thus allowing patients to tolerate higher, more therapeutic doses of THC. Besides its
effect on THC, CBD has been called a “multi-target” drug as it interacts with numerous
other non-endocannabinoid signaling system receptors such as G-protein-coupled
receptors, 5-HT1a receptor, and alpha 3 and alpha 1 glycine receptors for example.
CBD’s activation of multiple targets contributes to its many properties ranging from
analgesic, anti-inflammatory, antioxidant, anti-spasmodic, and anti-epileptic. (Devinsky
et al., 2014)
Pharmacokinetics. The pharmacokinetics of cannabis, or the absorption,
distribution, metabolism, and elimination of any drug is highly variable based on the
route of administration. Inhaled drugs enter the lungs and cross into the bloodstream at a
rate similar to if the drug was injected intravenously. Drugs taken orally, however, are
absorbed mainly through the small intestine but are subject to liver metabolism and
gastrointestinal (GI) variables such as drug-food interaction, drug-drug interaction, and
GI health (Whalen, 2019). The three most common methods of cannabis administration
are inhalation via smoking, inhalation via vaporization, and ingestion of edible products
(Bridgeman & Abazia, 2017). Cannabis comes in other forms such as pills, oil, topical
ointments and creams, liquid drinks, and suppositories. Method of administration
impacts the onset, intensity, duration of effect, as well as the effect on organ systems,
addictive potential and negative consequences associated with use (Bridgeman & Abazia,
2017; Madras, 2015). Thus, cannabinoid pharmacokinetic research has been challenging.
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Tetrahydrocannabinol and other cannabinoids are rapidly absorbed after
inhalation or intravenous administration with maximum brain concentration being
reached within 15 minutes (Bridgeman & Abazia, 2017). Maximum psychological and
physiological effects reach a plateau lasting two to four hours before slowly declining.
The amount absorbed varies between 20 and 45% of the THC content. When taken
orally, THC undergoes variable absorption depending on GI variables and has been
shown to have a narrower therapeutic window. Blood concentrations following oral
consumption have been shown to reach only 25-30% of those obtained by smoking the
same dose. Due to GI variables, onset of effect is also delayed 30 minutes to 2 hours
following oral consumption, with the duration of effect lasting five to six hours and
psychomotor and cognitive effects persisting much longer. is prolonged due to slow
absorption from the gut. (Bridgeman & Abazia, 2017) Cannabinoids do cross the
placenta, enter fetal circulation, penetrate breast milk, and accumulate in fatty tissues and
thus elimination from the body is very slow. Cannabinoids are metabolized by the liver,
contributing to large individual differences in rates of metabolism. (Bridgeman, 2017;
Kumar et al., 2001)
Adverse effects and safety considerations. The effects of cannabinoid
consumption are euphoria and relaxation, perceptual alteration, time distortion and the
intensification of normal sensory experiences. Short-term memory and attention, motor
skills, reaction time and skilled activities are impaired with impairments being dosedependent and potentiated with concomitant alcohol intake. Anxiety and panic reaction
are common and effects on the cardiovascular system include tachycardia with heart rate
increases of 20-50% within a few minutes lasting for up to 3 hours. Blood pressure tends
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to decrease when standing but not when sitting (Bridgeman & Abazia, 2017; Kumar et
al., 2001). The lethal dose of oral THC has been established in rats; however, no cases of
death due to toxicity following the maximum oral THC dose in dogs and monkeys
occurred (Grotenhermen, 2004). Acute fatal cases in humans have not been substantiated
to-date and long-term, large sample size studies have failed to show an increase in
cardiovascular mortality related to cannabis use (Frost, Mostofsky, Rosenbloom,
Mukamal, & Mittleman, 2013; Mukamal, Maclure, Muller, & Mittleman, 2008; Sidney,
Beck, Tekawa, Quesenberry, & Friedman, 1997). As THC is known to cause tachycardia
and increased cardiac output, its use may be associated with increased mortality in
patients with a history of myocardial infarction or increased risk of precipitating an acute
coronary event in susceptible patients (Kattoor & Mehta, 2016)
Isolated cannabinoids have undergone a number of randomized controlled trials
(RCTs) documenting safety, efficacy, and side effect profiles in order to formalize the
drug approval process for the three current pharmaceuticals including Marinol, Syndros,
and Epidiolex (FDA, 2019). Few RCTs are reported for whole plant cannabis and the
majority of trials have several limitations so the safety of cannabis cannot be assured at
this time without key information. (Madras, 2015; National Institute on Drug Abuse
[NIDA], 2019; Whiting et al., 2015)
A systematic review by Wang, Collet, Shapiro, and Ware (2008) evaluated a total
of 31 studies (N=3,122) including 23 RCTs examining the use of medical cannabinoids
and AEs. A total of 4,779 AEs were reported; 96.6% or 4,615 were not deemed by the
authors to be serious. The most common serious AEs included relapsing MS (9.1%; 15
events), vomiting (9.8%; 16 events), and urinary tract infections (9.1%; 15 events).
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Interestingly, no significant differences in the rates of serious adverse events between
individuals receiving medical cannabis and controls were identified (relative risk, 1.04;
95% CI, 0.78-1.39). The most commonly reported non-serious adverse event was
dizziness, with an occurrence rate of 15.5% (714 events). Other negative adverse effects
reported with acute cannabis use included hyperemesis syndrome, impaired coordination
and performance, anxiety, suicidal ideations or tendencies, and psychotic symptoms.
Chronic effects included mood disturbances, exacerbation of psychotic disorders,
cannabis use disorders, withdrawal syndrome, and neurocognitive impairments, as well
as cardiovascular and respiratory conditions (Wang et al., 2008).
Drug interactions may exist between cannabis and other pharmaceuticals
especially since hepatic cytochrome 450 (CYP 450) isoenzymes 2C9 and 3A4 play a
significant role in the primary metabolism of THC and CBDA, whereas 2C19 and 3A4
may be responsible for metabolism of CBD. Limited clinical trials have sought to
quantify this effect, but drug information data available on the two current cannabinoid
pharmaceuticals--Marinol and Syndros--reported altered THC and CBD levels with
concomitant administration of ketoconazole and rifampin. Additionally, smoking
cannabis may increase theophylline metabolism as is also seen after smoking tobacco
(Bridgeman & Abazia, 2017).
Cannabis and central nervous system impairment. The growing use of cannabis
worldwide has led to more recent increases in the number of human studies, especially
related to concerns of harmful effects. Neuroimaging techniques are being used to
determine the effects of cannabis on brain structure and function (Batalla et al., 2013).
Cognitive functions such as attention, concentration, decision-making, impulse control,
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reaction time, verbal fluency, and working memory had previously demonstrated
inconsistent acute impairment in a dose-dependent manner (Crean, Crane, & Mason,
2011). Several cognitive functions had also been shown to be impaired in recently
abstinent cannabis users for seven hours up to 20 days. Following sustained abstinence in
chronic, daily cannabis users, impairment in cognitive functioning continued for several
months with decision-making, planning, and concept formation being the most prominent
and durable deficits (Madras, 2015; Wadsworth, Moss, Simpson, and Smith, 2006).
A recent literature review by Mandelbaum and Monte (2017) reported the
existence of “strong evidence” that chronic cannabis abuse causes cognitive impairment
and physical damage to the brain, particularly white matter, theorized to be due to the
high saturation of CB1 receptors in that area. Similarly, Nader and Sanchez (2018)
systematically reviewed 13 neuropsychological studies addressing a variety of cognitive
domains, 25 structural neuroimaging studies, and 18 functional neuroimaging studies
comparing a group of regular cannabis users with a group of controls consisting of nonusers or individuals with very limited drug experience. Important findings confirmed the
most frequently affected cognitive domains to be executive functioning, memory,
attention, and learning. Evidence existed among thirteen studies reviewed that cognitive
impairment is reversible with scores on neuropsychological test battery (Halstead-Reitan
Battery) administered to cannabis users and control group demonstrating “virtually no
differences between the groups” (Nader & Sanchez, 2018, pg. 11). However other studies
such as one conducted by Meier et al. (2012) showed that those who initiating cannabis
use before the age of 18 resulted in persistent impairment following one year or more of
sustained abstinence.
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Nader and Sanchez’s (2018) systematic review of 22 structural neuroimaging
studies also confirmed the link between brain structure and connectivity. Findings
determined that whole brain volume was not affected by cannabis use, but that CB1-rich
areas such as the amygdala and hippocampus showed structural alterations. Functional
neuroimaging studies also revealed altered patterns of brain activities in cannabis users,
possibly due to upregulation of CB1 receptors. They concluded that the implications of
the structural and functional findings as a result of cannabis use are yet to be determined,
but added that even small impairment in cognitive functioning should be concerning.
Harmful effects to peripheral tissues. Chronic cannabis use has been associated
with an increased prevalence of symptoms of chronic bronchitis, inflammation to central
airways, and increased rates of respiratory infections and pneumonia comparable to that
of smokers of tobacco. Cannabis use has not been associated with adverse effects on
pulmonary function testing nor does it appear to contribute to chronic obstructive
pulmonary disease nor are its’ carcinogenic effects clear at the present times. Use has
been associated with increased risk of myocardial infarction (MI), stroke, and transient
ischemic attaches (TIA) during cannabis intoxication (Madras, 2015).
Carcinogenic potential. There is currently no consensus on whether cannabis use
is associated with overall cancer risk; however, cannabis smoke contains several of the
same carcinogens as tobacco smoke at up to 50% higher concentrations with three times
the tar per cigarette. In vitro and in vivo evidence has demonstrated pre-neoplastic
histological and molecular changes to respiratory mucosa exposed to chronic cannabis
smoke (Madras, 2015). A 2015 systematic review identified four cohort studies and 30
case-control studies investigating cannabis use and cancer risk: 11 studies on upper
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digestive cancers, six studies on lung cancer, three studies on testicular germ cell tumors,
six studies on childhood cancers, one study on all cancers, one study on anal cancer, one
study on penile cancer, two studies on non-Hodgkin lymphoma, one study on malignant
primary gliomas, one study on bladder cancer, and one study on Kaposi sarcoma (Huang
et al., 2015). The largest number of studies investigating the impact of cannabis and
cancer involve head and neck cancer. Pooled analyses reported no overall association for
head and neck cancer but a possible increased risk with dose response for oropharyngeal
cancer and a decreased risk for tongue cancers (Huang et al., 2015). Studies identifying
dosage and use found that even “highest exposure categories” rarely exceeded 10 jointyears of cumulative lifetime use which would translate into only 0.5 pack-years of
cigarette smoking. Thus, the smaller amounts of cannabis that are regularly smoked
compared with tobacco was suggested to explain the null association of cannabis with
lung cancer. The authors also discussed the tumor-suppressant effect of THC and other
cannabinoids which could possibly counteract the tumor-promoting effects of the
carcinogens. For the other cancers, the review concluded that there was still insufficient
data to make any conclusions whether an association existed between cancer and
cannabis use (Huang et al., 2015).
A more recent meta-analysis by Park and Myung (2018) also looked at lung
cancer. The analysis which included a total of 13,646 cancer patients and 151,572
participants without cancer. Results showed a marginally statistically significant
association between cannabis smoking and risk of lung cancer (OR=1.76, 95% CI 1.003.08). Subgroup analysis also showed an increase risk of testicular cancer when the
duration of cannabis smoking exceeded 10 years (OR=1.50; 95% CI, 1.02-2.09). Thus, as
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cannabis use rates continue to increase, well-designed, large-scale studies are necessary
to best determine the potential risks conferred by its use (Huang et al., 2015).
Cannabis during development. Accumulating evidence suggests that prenatal
exposure may interfere with normal development and maturation of the brain as children
exposed to cannabis in utero demonstrate impaired attention, learning, memory,
impulsivity, behavioral problems, and higher likelihood of using cannabis when they
mature (Sonon, Richardson, Cornelius, Kim, & Day, 2015). Regular, heavy cannabis use
during adolescence has been associated with cognitive deficits, impaired attention,
learning, memory, and IQ reduction. Brain imaging has also revealed changes in
adolescents or adults who initiated cannabis during adolescence such as smaller whole
brain and hippocampus, reduced cortical grey matter and insular cortical thickness
associated with level of use. Findings have obvious implications for education and also
have been associated with lower income level, lower college degree completion, greater
need for economic assistance, unemployment, and use of other drugs. (Madras, 2015;
Osuch et al., 2016).
Cannabis and society. In addition to the above, cannabis use continues to present
a widespread and serious personal and public health problem (Stinson, Ruan, Pickering,
& Grant, 2016). As cannabis use rises, an increasing burden on emergency services
documenting cannabis use alone or in combination with other drugs has increased. A
nationwide study by Dr. He Zhu and Dr. Li-Tzy Wu (2016) of Duke University Medical
Center showed that across the United States, between 2004 and 2011, emergency
department visits involving the use of cannabis increased from 51 to 73 per 100,000
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patients with those involving cannabis combined with other drugs also increased from 63
to 100 per 100,000.
Cannabis consumption impairs driving ability and confers a higher risk for motor
vehicle accidents. The effects of cannabis on cognition also affect work, employment,
performance, and everyday life, potentially increasing unemployment among users.
Cannabis for medical use has recently created dilemmas for the workplace, as ensuring
safety of workers who are under the influence or who recently consumed cannabis is not
possible (Madras, 2015).
Dependence, abuse, and cannabis use disorder (CUD). Classifying cannabis use in the
U.S. is dictated by the Diagnostic and Statistical Manual of Mental Disorders (DSM-V)
(2013). The World Health Organization’s (2019) International Statistical Classification
of Diseases and Related Health Problems (11th ed.; ICD-11) and DSM-V have
designated that cannabis is addictive and currently recognizes cannabis-related
dependence disorders. Generally, the effects of cannabis use can be understood as acute
and chronic. The acute phase includes intoxication and withdrawal states, along with
secondary complications: delirium; psychosis; anxiety; and insomnia. Chronic regular use
can be characterized by disordered behavior (APA, 2013; WHO, 2019).
Depending on the setting (i.e., Emergency Department, office visit, or
rehabilitation program), different effects of cannabis may be the focus and the diagnostic
criteria of the varying effects can be defined as: cannabis intoxication; cannabis
withdrawal; cannabis intoxication delirium; cannabis-induced psychotic disorder;
cannabis-induced anxiety disorder; cannabis-induced sleep disorder (APA, 2013).
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According to the latest World Drug Report published June of 2019 by the United
Nations Office on Drugs and Crime (UNODC), approximately 35 million people are
estimated to suffer from drug use disorders requiring treatment services. Approximately
13.1 million people globally are psychologically or physiologically dependent on
cannabis based on 2017 estimates by UNODC. Data from the US indicates that the
prevalence of cannabis use increases when perceived risk of use decreases. Perception of
risk has declined in the face of changing legal status of the drug, which researchers claim
has resulted in the rise in daily use among youth (Miech, Johnston, & O’Malley, 2017).
As a consequence of increased use, it comes as no surprise that the rate of reported CUD
in the US has climbed significantly (Madras, 2015).
Implications for Advanced Practice Nursing Education
As the use of both medical and recreational cannabis continues to rise, the fields
of public health, science, and education, as well as healthcare providers, must adjust to
support the needs of the population. Advanced practice registered nurses (APRNs),
including nurse practitioners, clinical nurse specialists, nurse anesthetists, and nurse
midwives, play a pivotal role in the future of health care and are increasingly the primary
care providers at the forefront of providing services to the public (ANA, 2018) .The
landmark document Consensus Model for APRN Regulation: Licensure, Accreditation,
Certification, and Education (NCSBN, 2008) delineates APRN roles and provides
recommendations about APRN licensure, accreditation, certification, and education.
According to the Consensus Model, APRNS must complete an accredited master’s or
doctorate program.
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APRN education. The American Nurses Association and Nurse Practice Acts
outline that APRNs must have sufficient depth and breadth of clinical experience as RNs,
and APRN education must build on their RN competencies. They must be prepared to
assume responsibility for health promotion and maintenance as well as assessment,
diagnosis, and management of patient problems, including the use and prescription of
nonpharmacologic ad pharmacologic interventions (ANA, 2018). Current APRN
programs require students to complete the “3 Ps”: advanced pharmacology; advanced
pathophysiology; and advanced physical health assessment. These foundational courses
require the maturation of foundational knowledge as well as the development of
advanced critical-thinking skills. Advanced practice registered nurses must meet clinical
competencies which are defined by patient-care needs, not practice setting, and must
maintain national certification and practice with a significant focus on direct patient care
(ANA, 2018).
Knowledge gaps. As awareness of and interest in the use of medical cannabis has
increased, it has become clear that health care professionals need to be involved in
management decisions but often feel unprepared and lacking in knowledge and education
necessary to engage in informed discussions with patients. Needs assessment surveys
have been used, mostly among physicians, to identify and rank the most common factors
involved in decision making about using cannabis for therapeutic purposes (Ziemianski et
al., 2015). Canada’s national program for access to medical cannabis began in 2001;
however, changes to the regulations which came into effect in August of 2016 allow
nurse practitioners (NPs) to authorize eligible patients access to medical cannabis
certification. This expansion in the NPs’ scope of practice prompted a national online
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survey of NPs to assess knowledge and practice gaps related to medical cannabis, with
the goal of informing the development of future education resources that increase clinical
competence and improve patient care related to medical cannabis (Balneave, Alraja,
Ziemianski, McCuaig & Ware, 2018).
The national online survey of NPs was adapted from the national survey
developed and used by Ziemianski et al. (2015). The survey consisted of six sections and
assessed current and desired level of medical cannabis knowledge, desire for medical
cannabis education, clinical experience related to medical cannabis, clinical barriers to
prescribing and providing care related to medical cannabis, attitudes regarding which
health care providers should be allowed to authorize medical cannabis use, and preferred
formal for future medical cannabis education (Balneave et al., 2018; Ziemianski et al.,
2015).
In 2013, there were 3,655 NPs eligible to practice in Canada. A convenience
sample of 552 NPs were recruited through email lists of nursing organizations, of which
227 accessed the national survey and 182 (33%) provided complete data for analysis.
Descriptive statistics summarized respondents’ demographic information, knowledge,
experiences, barriers, attitudes, and preference for educational approaches. Perceived
knowledge gap was calculated by computing the difference between individuals’ current
and desired knowledge level (i.e., only response pairs were used) (Balneave et al., 2018).
Results of the study demonstrated that respondents were most knowledgeable
about the potential uses (2.57/5.0) and risks (2.39/5.0) of medical cannabis as well as the
safety, warning signs, and precautions associated with medical cannabis use (2.21/5.0).
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The lowest mean knowledge level was for dosing and creating effective treatment plans
(1.63/5.0), similarities and differences across cannabis products (1.83/5.0), and the
current federal medical cannabis regulations (1.88/5.0) (Balneave et al., 2018).
Similar gaps in perceived knowledge and perceived needs concerning medical
cannabis have been identified by physicians, with the largest gaps between current and
desired knowledge concerning dosing, the development of treatment plans, and
comparisons between cannabis and existing prescription cannabinoids. There was an
expressed need for better knowledge of the risks and benefits of medical cannabis, with
respondents reporting that their comfort level in including medical cannabis in their
practice would increase with added education focusing on literature reviews, online, and
small group continuing medical education activities (Ziemianski et al., 2015).
Cannabis education in APRN nursing programs. Although recommending
medical cannabis is currently within the APRN scope of practice in US jurisdictions in
which the use of cannabis is legal for medical purposes, the majority of patient
certifications and recommendations have come from medical doctors (MD). Advanced
Practice Registered Nurses remain responsible for maintaining or seeking knowledge and
clinical competency related to patient care needs and clinical practice. Cannabis
classification as a Schedule I controlled substance has limited research and empirical
evidence supporting its effectiveness, and in turn medical and nursing education, has
lacked instruction related to the pharmacology, physiologic effects, uses, neurological
symptoms, drug-to-drug interactions, and adverse effects of cannabis. With the current
and projected prevalence of cannabis use by patients, it is clear that the addition of
curriculum content to provide APRNs with principles of safe and knowledgeable practice
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is warranted. In order for APRNs to continue ensure safe and appropriate patient care,
cannabis-specific curriculum content providing knowledge related to the current state of
legalization for medical and recreational use, the endocannabinoid system,
pharmacology, current research, and most importantly, safety considerations for the
patient using cannabis is necessary (NCSBN, 2018).
National Council of State Boards of Nursing (NCSBN) Guidelines. Sweeping
changes in societal attitudes towards cannabis, and the increasing use and legalization of
medical and recreational cannabis, prompted the National Council of State Boards of
Nursing (NCSBN) in 2017 to appoint members to a NCSBN Marijuana Regulatory
Guidelines Committee. Recognizing that nurses were unsure of their responsibilities in
the care of patients who may use cannabis, the committee was charged with exploring the
trends and issues related to cannabis use and nursing regulation in order to develop model
guidelines for APRNs care of patients. Committee findings prompted recommendations
for addition of curriculum content and the formation of model guidelines in the event
APRNs are to be able to provide certification of a qualifying condition under state
requirements (NCSBN, 2018).
An in-depth review of current scientific literature also included the greater
multitude of grey literature, or materials and research produced by organizations outside
of traditional academic publishing and distribution channels. The committee consulted
with known experts in the area of medical marijuana, its’ use, safety, and legislation. Prelicensure graduate-level education programs, as well as online educational content and
other information available to nurses, was surveyed and found to be significantly lacking
in providing knowledge for how to care for patients using cannabis (NCSBN, 2018).

29

The NCSBN review not only further highlighted the need for APRNs to have
practical information to care for the increasing number of patients utilizing cannabis, it
also established recommendations for APRN curriculum content as part of its national
nursing guidelines for medical marijuana. Recommendations included the APRN student
have a working knowledge of the current state of legalization, a working knowledge of
the principles of an MMP, an understanding of the endocannabinoid system, cannabinoid
receptors, cannabinoids, and the interactions between them, an understanding of cannabis
pharmacology and the research associated with the medical use of cannabis, the ability to
recognize signs and symptoms of cannabis use disorder and cannabis withdrawal
syndrome, the ability to identify the safety considerations for patients using cannabis,
and knowledge of administration and ethical considerations (NCSBN, 2018).
Next, the theoretical framework that will guide this study will be reviewed.
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Theoretical Framework
The Logic Model, developed by the W.K. Kellogg Foundation (2004), is a
beneficial tool that facilitates effective program planning, implementation, and
evaluation. A Logic Model is a systematic and visual way to develop a clear program
strategy based on the program’s desired results. A shared understanding of program
goals, activities, and intended outcomes is necessary to engage others and clearly relay
how a program will solve a particular problem.
The overarching purpose of the Logic Model is to serve as a visual road map,
connecting the purpose of the planned program with the program’s desired results. The
Logic Model serves as a program design and planning tool to better organize program
concepts, relationships, and structure. At the program implementation level, the Logic
Model helps identify and collect data needed for ongoing monitoring and improvement,
and as the model pictorially presents the components of the program, it clearly informs
progress towards goals and program evaluation (Schmitz & Parsons, 1999; W.K.
Kellogg, 2004).
The Basic Logic Model (Figure 1) includes five components: resources; program
activities; outputs; outcomes; and impact. Resources include the human, financial,
organizational, and community resources a program has available to accomplish the
activities. The program activities are processes, tools, events, actions, and interventions
used to address the problem the program seeks to change. Outputs are the direct products
of the program activities, or the evidence that the program has been delivered. Outcomes
can be both short and long-term and include specific changes expected at the individual
or program participant level resulting from the program, while impact is the long-term
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intended or unintended change occurring at the organizational, community, or systems
level as a result of the program. (Shakman & Rodriguez, 2015; W.K. Kellogg, 2004)

Figure 1. The Basic Logic Model
Next, the method will be presented.
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Method
Purpose
The purpose of the project was to evaluate the impact of a teaching module
intended to provide essential knowledge and clinical implications of medical cannabis for
the APRN student.
Design
This program development project included a pre-test, intervention, post-test
design. The pre-test, or pre-video survey, was used to determine perceived current level
of knowledge of medical cannabis among APRN student participants. The intervention,
an educational video was developed to educate APRN students on essential knowledge
for medical cannabis. A post-video survey was administered after student completion of
the educational video to measure improved knowledge.
Sample and Site
Advanced practice registered nurse students at Rhode Island College, School of
Nursing (RIC SON), enrolled in Fall 2019 and Spring 2020 Nursing 505 Advanced
Pharmacology, as well as Spring 2020 Nursing 620 were asked to participate in the study.
The IRB approved informational letter, pre-video survey, and post-video survey were
handed out prior to the start of class and the link to the educational video to be found
online was given to students. The educational video consisted of a narrated PowerPoint
presentation uploaded to YouTube.
The Logic Model Framework
Resources/Inputs. Collaboration with Nursing 505 and 620 faculty confirmed the
absence of medical cannabis knowledge within the current curriculum. Advanced
practice registered nurse students enrolled in Nursing 505 and 620 were the targeted
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group receiving the educational video. The program developer collaborated with course
faculty to integrate the video into course curriculum. Clinical guidelines from the
National Council of State Boards of Nursing (NCSBN) National Nursing Guidelines for
Medical Marijuana (2018) were used to guide the content of the educational video. The
program developer collaborated with APRNs from the NCSBN Regulatory Implications
of Legal Cannabis Committee, who developed the guidelines, to review program content
and assist as experts on this topic.
Activities/Procedures. The project proposal was accepted by the RIC IRB for
review. The program developer completed the educational video. In collaboration with
NURS 505 and 620 faculty, a date was selected for introduction of the study immediately
before class. The program developer discussed the purpose of the study--to provide the
APRN student with essential knowledge and clinical implications related to medical
cannabis--and intended goals were discussed. Students were informed that the
educational video was a required assignment, however completion of the pre- and postvideo survey was voluntary and anonymous. The educational video was a 30-minute
narrated PowerPoint presentation which students were given the link to access online. A
numbered pre- and post-video survey packet was handed out to students in class. The
IRB approved informational letter explaining the purpose of the study as well as
instructions for completing the pre-video survey followed by viewing the educational
video, and the completing the post-video survey was also within this packet. Dates for
completion of the pre-video survey, educational video, and post-video survey were
assigned. Students were given two weeks to return the pre-video survey, two weeks to
view the educational video, and two weeks to return the post-video survey. An email was
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sent to all enrolled students three days prior to classes when surveys were due reminding
them to bring their returned survey to class. An email was sent reminding them to view
the educational video three days before the due date. Surveys were anonymous and
results confidential. Completed survey packets were returned by students immediately
before class or during class break to a manila folder and the program developer was
available to pick the folder up following class the two weeks the pre- and post-video
surveys were due.
Activities/Program Development. An educational video geared toward APRN
students based on recommended essential knowledge for medical cannabis (NCSBN,
2018) was developed. Content included: overview of current state of legalization of
medical and recreational cannabis; principles of a medical marijuana program (MMP);
endocannabinoid system; cannabis pharmacology and the research associated with the
medical use of cannabis; signs and symptoms of cannabis use disorder and cannabis
withdrawal syndrome; and safety considerations for patient use of cannabis. Content was
generated directly from NCSBN guidelines described in Table 1. Prior to
implementation, the program developer submitted the presentation to NCSBN advanced
practice nurse collaborator for review and clarity of content.
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Table 1
Essential Knowledge Elements of APRN Student Educational Module
Purpose of Educational Module and
NCSBN Guidelines
Definitions

Current State of Legalization
Principles of an MMP
The Endocannabinoid System (ECS)
Cannabis Pharmacology and Research

Clinical Encounter Considerations

Medical Cannabis Administration
Considerations
Ethical Considerations

Cannabis; Cannabidiol (CBD);
Cannabinoid; Tetrahydrocannabinol
(THC); Medical Marijuana Program
(MMP)
DEA; Schedule I Controlled Substance
categorization, MMPs
Department of Health statues; Health
care provider responsibilities; Certifying;
Qualifying conditions; APRN role
Discovery of ECS; Overview; Purpose;
Cannabinoid receptors; Enzymes; THC,
CBD, and CBN
Current scientific evidence; Levels of
evidence; Indications supported by
evidence; Adverse effects; Routes of
administration; Risks to particular groups
of patients
Signs and symptoms of cannabis adverse
effects; Identification of safety
considerations; Cannabis Use Disorder
(CUD)
Hospitalized patient considerations;
FDA-approved synthetic THC
medications; Providers as MMPdesignated caregivers
Patient care without judgement

The educational video was tailored to meet the scheduling needs of both the
students and the course, and included a 30-minute, narrated PowerPoint presentation that
students had two weeks to complete. For ease of access, the educational video was
uploaded to YouTube and the students were given the link to view the video. As a course
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assignment, the educational video did not interfere with the current course curriculum or
in-class time.
Outputs/Measurement. The goal was to have all APRN students enrolled in Fall
2019 Nurs 505, Spring 2020 Nurs 505, and Spring 2020 Nurs 620 complete the
educational video as well as the pre- and post-video survey. The pre- and post-video
surveys were identical and consisted of nine knowledge items (see Appendix A). The
concept of the knowledge survey was taken from a national needs-based survey
developed and piloted by Canadian researchers Ziemianski et al. (2015). The entire
survey by Ziemianski et al. consisted of six sections-- knowledge, experience, barriers,
attitudes, educational opportunities, and demographics--with varying numbers of items.
For the purpose of this study, the pre- and post-video survey only consisted of a
knowledge section.
The nine knowledge items from Ziemianski et al.’s survey prompted respondents
to rank their perceived current level of knowledge on nine medical marijuana-related
topics (see Table 2) using a 5-point Likert scale (1: very poor; 2: somewhat poor; 3:
undecided; 4: somewhat good; and 5: very good). The nine items were utilized to identify
Canadian physician’s perceived knowledge gaps and perceived needs concerning
cannabis for therapeutic purposes. The concept of Ziemianski, et al.’s survey was
combined with NCSBN (2018) recommended essential knowledge elements for medical
marijuana education in APRN nursing programs found in Table 1. Knowledge areas
evaluated are listed in Table 2 on the next page.
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Table 2
Knowledge Areas Evaluated
Knowledge area
Current state of legalization of medical and recreational cannabis use.
Principles of a Medical Marijuana Program (MMP).
The endocannabinoid system, cannabinoid receptors, cannabinoids, and the
interactions between them.
Cannabis pharmacology and research associated with the medical use of cannabis.
Signs and symptoms of cannabis use disorder and cannabis withdrawal syndrome.
Safety considerations for patient use of cannabis.
Medical marijuana administration considerations.
Ethical considerations related to the care of a patient using medical marijuana.
APRN role regarding certifying a qualifying condition.

The effectiveness of the educational video was evaluated by the nine-item postvideo survey which was identical to the pre-video survey (see Appendix A) with the
addition of a question which asked students if they completed the online educational
video. Participants rated their perceived current level of knowledge for each of the nine
items using the same Likert scale as Ziemianski et al. (1: very poor; 2: somewhat poor; 3:
undecided; 4: somewhat good; and 5: very good).
Additionally, both pre- and post-video surveys included a question which asked
respondents to rate their perceived level of importance of integrating education on
cannabis into the APRN curriculum. They rated their perceived level of importance using
a 5-point-Likert scale (1: not at all important; 2: slightly important; 3: neutral; 4:
moderately important; 5: extremely important). The mean perceived level of importance
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was calculated for all pre-video survey responses, calculated for all post-video survey
responses, and the difference between the post-video and pre-video means was
calculated.
Outcomes
The short-term outcome of the educational video was to increase APRN student
essential knowledge on medical cannabis and provide them with the NCSBN
recommended essential knowledge elements for medical marijuana education in APRN
nursing programs. Though beyond the scope of this project, the long-term goal is to
incorporate the NCSBN recommended essential knowledge content into all accredited
APRN education programs. Providing APRN students with principles to guide safe and
knowledgeable practice will promote patient safety when caring for patients using
cannabis.
Data Analysis
Descriptive statistics summarize respondents’ knowledge ratings. Data were
entered and analyzed using Microsoft Excel. Perceived current level of knowledge prevideo was calculated by computing the mean respondent score for each item. The mean
perceived level of knowledge post-video score was also calculated for each of the nine
items. The increase in perceived level of knowledge was calculated by finding the
difference between the mean response score for each of the nine pre-video survey
questions and the mean response score for all post-video survey questions. Change in
perceived level of importance with regard to integrating education on cannabis into the
APRN curriculum was calculated by computing the difference in between the mean score
for this item on pre-video and post-video surveys.
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Data were analyzed for the survey question which asked respondents to rate their
perceived level of importance of integrating education on cannabis into the APRN
curriculum. Based on their perceived level of importance rating, the mean perceived level
of importance was calculated for all pre-video survey responses, calculated for all postvideo survey responses, and the difference between the post-video and pre-video means
was calculated.
Next, the results will be presented.
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Results
Participants’ Demographics
Participants in this study included Rhode Island College graduate nursing students
enrolled in Advanced Pharmacology, Nurs 505, in the Fall of 2019 or Spring of 2020, as
well as those graduate students enrolled in Nurs 620 during Spring of 2020. A total of 24
students completed the pre-video survey and a total of 19 students completed the postvideo survey.
Perceived Level of Knowledge Before Educational Video
Table 3 illustrates the analysis of study participants’ perceived level of knowledge
on the nine knowledge area questions on the pre-video survey. The mean of all
participant pre-video scores for all nine areas are presented.
Table 3
Analysis of Perceived Level of Knowledge Before Educational Module
Knowledge items
(1-5)
1 - Current state of legalization of medical and
recreational cannabis use.
2 - Principles of a Medical Marijuana Program (MMP).
3 - The endocannabinoid system, cannabinoid receptors,
cannabinoids, and the interactions between them.
4 - Cannabis pharmacology and research associated with
the medical use of cannabis.
5 - Signs and symptoms of cannabis use disorder and
cannabis withdrawal syndromes.
6 - Safety considerations for patient use of cannabis.
7 - Medical marijuana administration considerations.
8 - Ethical considerations related to the care of a patient
using medical marijuana.
9 - APRN role regarding certifying a qualifying condition.

Mean knowledge score

2.96
1.96
1.92
2.04
2.54
2.67
2.54
2.67
1.83
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Mean knowledge scores ranged from 1.83/5.0 to 2.96/5.0. Prior to watching the
educational video, respondents perceived that they were most knowledgeable about
current state of legalization (2.96/5.0), safety considerations (2.67/5.0), ethical
considerations (2.67/5.0), signs and symptoms of cannabis use disorder and cannabis
withdrawal (2.54/5.0), and administration considerations (2.54/5.0). In contrast, the
lowest mean perceived level of knowledge was for the APRN role (1.83/5.0), the
endocannabinoid system (1.92/5.0), principles of a Medical Marijuana Program
(1.96/5.0), and cannabis pharmacology (2.04/5.0).
Perceived Level of Knowledge Post Educational Video
Table 4 illustrates the analysis of study participants’ perceived level of knowledge
on the nine knowledge area questions on the post-video survey. The mean of all
participant post-video scores for all nine areas are presented on the next page.
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Table 4
Analysis of Perceived Level of Knowledge After Educational Module

Knowledge items

Mean knowledge score (1-5)

1 - Current state of legalization of medical and
recreational cannabis use.
2 - Principles of a Medical Marijuana Program (MMP).
3 - The endocannabinoid system, cannabinoid receptors,
cannabinoids, and the interactions between them.
4 - Cannabis pharmacology and research associated with
the medical use of cannabis.
5 - Signs and symptoms of cannabis use disorder and
cannabis withdrawal syndromes.
6 - Safety considerations for patient use of cannabis.
7 - Medical marijuana administration considerations.
8 - Ethical considerations related to the care of a patient
using medical marijuana.
9 - APRN role regarding certifying a qualifying condition.

4.63
4.53
4.58
4.42
4.79
4.74
4.74
4.63
4.47

The mean score on all post-video survey knowledge items ranged from 4.42/5.0 to
4.79/5.0. Following the educational video, respondents perceived that they had a greater
than “somewhat good” level of knowledge on all knowledge items. They had the highest
perceived knowledge on signs and symptoms of cannabis use disorder and cannabis
withdrawal syndromes (4.79/5.0), safety considerations for patient use of cannabis
(4.79/5.0), and medical marijuana administration considerations (4.74/5.0).
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Table 5 illustrates the analysis of the increase in study participants’ perceived
level of knowledge following the educational video.
Table 5
Analysis of Difference in Perceived Level of Knowledge Pre- and Post-Educational
Module

Knowledge items
1 - Current state of legalization of medical and
recreational cannabis use.
2 - Principles of a Medical Marijuana Program (MMP).
3 - The endocannabinoid system, cannabinoid receptors,
cannabinoids, and the interactions between them.
4 - Cannabis pharmacology and research associated with
the medical use of cannabis.
5 - Signs and symptoms of cannabis use disorder and
cannabis withdrawal syndromes.
6 - Safety considerations for patient use of cannabis.
7 - Medical marijuana administration considerations.
8 - Ethical considerations related to the care of a patient
using medical marijuana.
9 - APRN role regarding certifying a qualifying condition.

Change in knowledge
score (1-5)
+1.67
+2.57
+2.66
+2.38
+2.25
+2.07
+2.20
+1.96
+2.64

The survey knowledge items with the greatest increase in perceived level of
knowledge (i.e., perceived level of knowledge post-video – perceived level of knowledge
pre-video) following the educational video were as follows: the endocannabinoid system;
cannabinoid receptors; cannabinoids; and the interactions between them, the APRN role
regarding certifying a qualifying condition; and principles of a Medical Marijuana
Program. While the mean perceived level of knowledge on pre-video knowledge items
ranged from 1.83–2.96/5.0, the mean on all post-video knowledge items ranged from
4.44–4.79/5.0.
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Importance of Cannabis Education
Table 6 illustrates the analysis of study participants’ perceived level of
importance with regard to integrating education on cannabis into the APRN curriculum.
Table 6
Analysis of Difference in Perceived Level of Importance of Education on Cannabis in
APRN Curriculum
Mean score (1-5)
Pre-Video Survey

4.45

Post-Video Survey

4.76

The mean score for the perceived importance of integrating cannabis education
into the APRN curriculum increased from 4.45/5.0 on pre-video surveys to 4.77/5.0 on
post-video surveys.
Next, the summary and conclusions will be presented.
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Summary and Conclusions
As interest in medical cannabis continues to grow in the United States, healthcare
providers, including APRNs, will be faced with increasing requests for information and
guidance from patients regarding the use of medical cannabis for health-related issues.
With federal regulations allowing APRNs to certify a qualifying condition, APRNs may
also become a major source of education, decision support, and access for patients.
Literature has examined the knowledge and practice gaps related to medical cannabis in a
national sample of Canadian physicians and nurse practitioners and the findings have
demonstrated a strong need for education on all aspects of cannabis (Balneaves et al.,
2018; Ziemianski et al., 2015).
The NCSBN study (2018) results informed specific guidelines: nursing care of the
patient using medical marijuana; medical marijuana education in pre-licensure nursing
programs; medical marijuana education in APRN nursing programs; and APRNs
certifying a medical marijuana qualifying condition. The Logic Model (2004) was used
as a framework to effectively plan the and incorporate the NCSBN guidelines into an
effective educational module, implement the intervention, and evaluate the outcome of
the project.
The purpose of the project focused on evaluating the impact of the educational
module designed to provide the NCSBN essential knowledge elements of medical
cannabis to the APRN student. The educational module was a 30-minute narrated
PowerPoint presentation which students viewed at home as part of their course
curriculum. A pre-video survey was used to determine perceived current level of
knowledge of medical cannabis among APRN student participants prior to watching the
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educational video and a post-video survey was administered after student completion of
the video to measure improved knowledge.
Descriptive statistics summarized respondents’ knowledge ratings on both preand post-video surveys. The change in perceived level of knowledge following the
educational video was calculated by finding the difference between the mean response
score for each of the nine pre-video survey questions and the mean response score for all
post-video survey questions. An additional survey question asked respondents to rate
their perceived level of importance with regard to integrating education on cannabis into
the APRN curriculum. The change in response following the educational module for this
question was also calculated by computing the difference in the mean score for this item
on pre-video and post-video surveys.
When using the NCSBN guidelines for medical marijuana education in APRN
nursing programs, and the nine essential knowledge recommendations, this project
demonstrated that, at baseline APRN students’ perceived level of knowledge for all
knowledge items was between very poor and neutral. If the knowledge items represent
essential knowledge necessary to provide safe patient care to patients using medical or
recreational cannabis, this low level of perceived knowledge is concerning. This low
level of perceived knowledge also supports the integration of these essential knowledge
recommendations into APRN curriculum in order to best care for the increasing number
of patients using cannabis.
The largest knowledge gaps identified were related to background knowledge of
cannabis, the endocannabinoid system, cannabis pharmacology, and the APRN role in
certifying a qualifying condition. This knowledge could easily be integrated into the
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theory component of upper level course curriculum. Advanced practice registered nurse
students perceived their knowledge of the more clinical elements better but still
somewhat poor. These knowledge elements, such as signs and symptoms of cannabis use
disorder and cannabis withdrawal syndrome, safety considerations, administration
considerations, and ethical considerations could most likely be incorporated into the
clinical competency portion of the curriculum. Students could be encouraged to address
these elements with at least one patient over the course of their 600-direct-patient-carehour requirement.
Another option for increasing APRN students’ perceived level of knowledge
related to cannabis would be the integration of an educational video module similar to the
one developed for this study. The video module provided the APRN student with
pertinent information related to each of the nine essential knowledge elements outlined
by the NCSBN study. Following the video, APRN students perceived knowledge was at
least “somewhat good”, if not “very good” on all nine items. Furthermore, prior to the
educational video, students rated their perceived level of knowledge as “somewhat good”
or “very good” only 22% of the time compared to 99% of the time after watching the
video. If “somewhat good” or “very good” perceived level of knowledge is identified as
the goal which curriculum should meet, the educational video intervention met the goal
of increasing student perceived level of knowledge to an adequate level. Students
perceived that their level of knowledge increased the most in the knowledge items related
to principles of a Medical Marijuana Program, the endocannabinoid system, and the
APRN role regarding certifying a qualifying condition.
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The APRN student respondents perceived the importance of integrating education
on cannabis into the APRN curriculum as moderately and extremely important both
before and after watching the educational video. This perceived level of importance
suggests that students believe that knowledge related to cannabis is, and/or will be,
essential to their role as an APRN. Students expect that curriculum is preparing them
with the knowledge necessary to fulfill the APRN role and provide appropriate and safe
patient care. Thus, APRN student perception that integration of cannabis education into
the APRN curriculum is moderately to extremely important may support funding for a
gap analysis and proposed areas of integration into current course curriculum.
Limitations to these findings must be noted such as the small sample size, which
represented only a small percentage of APRN students. As a convenience sample, APRN
students who participated in the study may have held a unique perspective or interest in
medical cannabis not representative of the larger APRN student or APRN community.
Also, due to the fact that watching the educational video was an ungraded course
assignment, there was no way to confirm whether all participants completing post-video
surveys had completed the educational module.
In summary, given the limited amount of knowledge related to medical cannabis
in the current APRN curriculum together with the increasing prevalence of its use, the
findings remain relevant and will inform future education programming.
Next, recommendations and implications for APRN education and practice.
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Recommendations and Implications for Advanced Nursing Practice
As the demand for medical cannabis increases and the prevalence of patients
using cannabis for medical purposes continues to rise, education within APRN programs,
as well as continuing education for those in practice, is urgently needed to ensure safe
patient care. The NCSBN National Nursing Guidelines for Medical Marijuana Education
in APRN Nursing Programs, which outlines nine essential knowledge principles
necessary for APRN students, should be reviewed and incorporated into accredited
APRN course curriculum. Accredited programs should perform a gap analysis in order to
identify existing content and course objectives, as well as to identify the most appropriate
content areas to integrate the recommended knowledge principles.
Advanced practice registered nursing education should include essential
knowledge such as: the current state of legalization of medical and recreational cannabis
use; principles of an MMP; the endocannabinoid system, cannabinoid receptors,
cannabinoids, and the interactions between them; cannabis pharmacology and the
research associated with medical use of cannabis; signs and symptoms of cannabis use
disorder and cannabis withdrawal syndrome; safety considerations for patient use of
cannabis, medical marijuana administration considerations; ethical considerations related
to the care of a patient using medical marijuana; and the need to follow specific employer
policies and procedures, standard of care arrangements, and facility policy and
procedures regarding certifying a qualifying condition.
Integration of essential medical cannabis knowledge into APRN education can be
accomplished by following the NCSBN National Nursing Guidelines for Medical
Marijuana Education in APRN Nursing Programs and expanding various areas of
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program curriculum. For example, essential cannabis knowledge could be integrated into
advanced pharmacology course content through the development of a tailored online
education program or educational video inclusive of all knowledge elements such as the
video used in this project. Essential knowledge could be added to lecture material or
assigned as additional course required material or reading. Online continuing professional
development and in-person seminars, fulfilling student conference hour requirements, is
another educational strategy option.
Additionally, there is an ongoing need for clinical evidence-based research on the
use of cannabis for medical purposes. A more robust body of literature will best inform
clinical practice guidelines and support all healthcare practitioners in providing effective
and safe patient care. More information regarding student APRN and licensed APRN
knowledge, attitudes, and beliefs surrounding medical cannabis is necessary to inform the
most effective educational strategies for integrating knowledge into curriculum and
continuing education.
As the APRN scope of practice authorizes certification of a qualifying condition,
APRNs need to be supported and provided education appropriate to fulfill this role and
provide safe patient care. As state legislative bodies create MMP requirements, policy
should ensure a minimum educational requirement for medical cannabis be met by
certifying practitioners. Similar to the mandatory opioid/pain management CEUs many
states have adopted, states with MMPs should mandate medical cannabis CEUs to ensure
providers have a basic knowledge necessary to appropriately care for this expanding
patient population. In the meantime, nursing regulatory organizations, government
agencies, and academic institutions must work collaboratively to identify knowledge
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gaps, tailor educational programs, and outline clinical competencies specific to medical
cannabis knowledge clinicians will use in practice.
In summary, recommending medical cannabis and certifying a medical marijuana
qualifying condition is within the APRN scope of practice within US jurisdictions which
have legalized cannabis for medical use. As licensed healthcare providers, APRNs are
responsible for maintaining or seeking knowledge and clinical competency related to
patient-care needs and clinical practice. In order to ensure safe and appropriate patient
care, APRN programs must stay up-to-date on matters of common interest and concern
affecting the public health, safety, and welfare. Educational programs must also ensure
curriculum supports the development of knowledge applicable to licensing examinations
which organization such as the NCSBN aid in developing.
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Appendix A
PRE-ASSIGNMENT SURVEY
1) Please rank your perceived current level of knowledge on the nine (9) cannabis-related
topics below.
5 = very good

4 = somewhat good

3 = undecided

2 = somewhat poor

1 = very poor

Knowledge area
1 - Current state of legalization of medical and recreational
cannabis use.

5

4

3

2

1

2 - Principles of a Medical Marijuana Program (MMP)

5

4

3

2

1

3 - The endocannabinoid system, cannabinoid receptors,
cannabinoids, and the interactions between them.

5

4

3

2

1

4 - Cannabis pharmacology and research associated with the
medical use of cannabis.

5

4

3

2

1

5 - Signs and symptoms of cannabis use disorder and cannabis
withdrawal syndrome.

5

4

3

2

1

6 - Safety considerations for patient use of cannabis.

5

4

3

2

1

7 - Medical marijuana administration considerations.

5

4

3

2

1

8 - Ethical considerations related to the care of a patient using
medical marijuana.

5

4

3

2

1

9 - APRN role regarding certifying a qualifying condition.

5

4

3

2

1

2) In terms of integrating education on cannabis into the APRN curriculum, please circle
your perceived level of importance.
5 = Extremely important
4 = Moderately important
3 = Neutral
2 = Slightly important
1 = Not at all important

